DOCSLIB.ORG

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer Author Manuscript Published OnlineFirst on June 13, 2018; DOI: 10.1158/1078-0432.CCR-18-0267 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer Maria Saigi1*, Juan J Alburquerque-Bejar1*, Anne Mc Leer-Florin2, Carolina Pereira1, Eva Pros1, Octavio A. Romero1, Nuria Baixeras3, Anna Esteve-Codina4,5, Ernest Nadal6,7, Elisabeth Brambilla2and Montse Sanchez-Cespedes1 1Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. 2Département d’Anatomie et Cytologie Pathologiques, Pôle de Biologie et Pathologie, CHU Grenoble Alpes, Grenoble and Université Grenoble Alpes, Grenoble, France. 3Pathology Department, Bellvitge University Hospital, Hospitalet de Llobregat, Spain. 4CNAG-CRG, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain. 5 Universitat Pompeu Fabra (UPF), 6Department of Medical Oncology, Catalan Institute of Oncology (ICO), Hospitalet de Llobregat, Barcelona, Spain. 7Clinical Research in Solid Tumors (CReST) Group, OncoBell Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Barcelona, Spain. Corresponding author: Montse Sanchez-Cespedes, Genes and Cancer Group, Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908, Hospitalet de Llobregat, Barcelona, Spain. Email: [email protected] *Both authors contributed equally to this work Disclosure of Potential Conflicts of Interest: E Nadal has received consultancy fees from Pfizer and Roche. No potential conflicts of interest were disclosed by the other authors. Running title: MET activity, JAK2 inactivation and PD-L1 expression in lung cancer Key words: PD-L1, immunotherapy, MET, JAK2, lung cancer, interferon gamma Saigi M, Alburquerque-Bejar JJ et al. 1 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 13, 2018; DOI: 10.1158/1078-0432.CCR-18-0267 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract Purpose: The blockade of immune checkpoints such as PD-L1 and PD-1 is being exploited therapeutically in several types of malignancies. Here, we aimed to understand the contribution of the genetics of lung cancer (LC) to the ability of tumor cells to escape immunosurveillance checkpoints. Experimental Design: Over 150 primary non-small cell lung cancers, including pulmonary sarcomatoid carcinomas, were tested for the levels of HLA-I complex, PD-L1, tumor-infiltrating CD8+ lymphocytes and alterations in main LC genes. Correlations were validated in cancer cell lines using appropriate treatments to activate or inhibit selected pathways. We also performed RNA sequencing to assess changes in gene expression after these treatments. Results: MET-oncogenic activation tended to associate with positive PD-L1 immunostaining, whereas STK11 mutations were correlated with negative immunostaining. In MET-altered cancer cells, MET triggered a transcriptional increase of PD-L1 that was independent of the IFNγ-mediated JAK/STAT pathway. The activation of MET also up-regulated other immunosuppressive genes (PDCD1LG2 and SOCS1), and transcripts involved in angiogenesis (VEGFA and NRP1) and in cell proliferation. We also report recurrent inactivating mutations in JAK2 that co-occur with alterations in MET and STK11, which prevented the induction of immunoresponse-related genes following treatment with IFNγ. Conclusions: We show that MET activation promotes the expression of several negative checkpoint regulators of the immunoresponse, including PD-L1. In addition, we report inactivation of JAK2 in LC cells that prevented the response to IFNγ. These alterations are likely to facilitate tumor growth by enabling immune tolerance and may affect the response to immune checkpoint inhibitors. Saigi M, Alburquerque-Bejar JJ et al. 2 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 13, 2018; DOI: 10.1158/1078-0432.CCR-18-0267 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Translational Relevance The ability of tumors to avoid host immune surveillance through the blockade of PD-L1 and PD-1 is being exploited therapeutically. However, few biomarkers are currently well-established predictors of the response to these treatments. Here we found that activation of MET in lung cancer triggers a transcriptional increase of PD-L1. This was framed within a more generic transcriptional activation of immunosuppression-related molecules. We also report recurrent inactivating mutations at JAK2 that impair the up-regulation of immunoresponse-related transcripts when treated with IFNγ. Therefore, MET and JAK2 alterations in lung cancer contribute to promote immunotolerance and may constitute biomarkers for predicting responsiveness to immunotherapies in this type of cancer. Saigi M, Alburquerque-Bejar JJ et al. 3 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 13, 2018; DOI: 10.1158/1078-0432.CCR-18-0267 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Introduction A hallmark of cancer biology is the ability of tumors to avoid host immune surveillance. This characteristic has turned out to be therapeutically exploitable in novel immunotherapies (1). Several alterations in cancer cells are known to impair immune surveillance. These include defects in tumor immunorecognition, such as down-regulation of the HLA-I complex due to gene alterations of its components (either B2M or HLA-A) or at molecules involved in its maturation process (e.g. CALR, TAP1/2, TAPBP) (2-4). An abnormal increase in the expression of negative controllers of the immune response, such as constitutively high levels of programmed death ligand-1 (PD-L1) expression, also contributes to immune tolerance (1). The programmed cell death-1 (PD-1) receptor is expressed in activated T and B cells and regulates the cellular and humoral immune responses by interacting with its cognate ligand, PD- L1, which is expressed in the macrophage lineage and in some carcinomas, including lung cancer (LC) (5). The interaction of PD-1 with PD-L1 attenuates the immune response by inhibiting T-cell proliferation and functions (1,5). The blockade of these checkpoints is the means by which therapeutic agents are intended to enhance tumor immunological responses. In non-small cell lung cancer (NSCLC), anti-PD-1/-PD-L1 therapies have yielded clinical responses and increases in overall survival in subsets of patients (6-8). This clinical benefit makes it crucial to identify factors that determine the sensitivity or refractoriness to immune checkpoint inhibitors (ICIs). Several functionally interrelated tumor biomarkers have been proposed as predictors of the response to ICIs, including high tumor mutational load, DNA mismatch repair deficiency, strong intratumoral T cell infiltration and a high level expression of PD-L1 and of the HLA-I-class complex (4, 6-9). In addition, inactivating mutations of JAK2 in melanoma, involved in IFNγ-signaling, and of B2M in melanoma and in LC, account for primary and acquired resistance to these treatments (4, 10-11). Although somewhat controversial, the levels of PD-L1 protein are among the current main criteria for selecting patients to receive anti-PD-1 or anti-PD-L1 therapies for LC (12-13). Since Saigi M, Alburquerque-Bejar JJ et al. 4 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 13, 2018; DOI: 10.1158/1078-0432.CCR-18-0267 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. these molecules are direct targets of immunotherapy, it is of great interest to understand the intrinsic molecular and genetic events that modulate their expression in cancer cells. Some researchers have proposed that genetic activation of growth factor receptors in LC, such as EGFR, ALK and ROS1, are associated with a high level of expression of immunocheckpoint proteins, including PD-L1 (14-16). Finally, TP53/KRAS-co-mutated tumors have also been proposed to be associated with increased expression levels of PD-L1 and with a notable clinical benefit to those patients who are treated with PD-1 inhibitors (17). However, the results so far are not conclusive (12, 18). Our current work aims to understand the contribution of LC genetics to the ability of tumor cells to escape immunosurveillance. Saigi M, Alburquerque-Bejar JJ et al. 5 Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2018 American Association for Cancer Research. Author Manuscript Published OnlineFirst on June 13, 2018; DOI: 10.1158/1078-0432.CCR-18-0267 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Materials and Methods Tumor samples and cancer cell lines Tumor specimens were collected from patients newly diagnosed with NSCLC at
Load more

Recommended publications
  • Mutation Analysis in Myeloproliferative Neoplasms AHS - M2101
    Corporate Medical Policy Mutation Analysis in Myeloproliferative Neoplasms AHS - M2101 File Name: mutation_analysis_in_myeloproliferative_neoplasms Origination: 1/1/2019 Last CAP review: 8/2021 Next CAP review: 8/2022 Last Review: 8/2021 Description of Procedure or Service Myeloproliferative neoplasms (MPN) are a heterogeneous group of clonal disorders characterized by overproduction of one or more differentiated myeloid lineages (Grinfeld, Nangalia, & Green, 2017). These include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The majority of MPN result from somatic mutations in the 3 driver genes, JAK2, CALR, and MPL, which represent major diagnostic criteria in combination with hematologic and morphological abnormalities (Rumi & Cazzola, 2017). Related Policies: BCR-ABL 1 Testing for Chronic Myeloid Leukemia AHS-M2027 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for mutation analysis in myeloproliferative neoplasms when it is determined to be medically necessary because the medical criteria and guidelines shown below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. When Mutation Analysis in Myeloproliferative Neoplasms is covered 1. JAK2, CALR or MPL mutation testing is considered medically necessary for the diagnosis of patients presenting with clinical, laboratory, or pathological findings suggesting classic forms of myeloproliferative neoplasms (MPN), that is, polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF) when ordered by a hematology and/or oncology specialist in the following situations: A.
    [Show full text]
  • Promoter Janus Kinase 3 Proximal Characterization and Analysis Of
    The Journal of Immunology Characterization and Analysis of the Proximal Janus Kinase 3 Promoter1 Martin Aringer,2*† Sigrun R. Hofmann,2* David M. Frucht,* Min Chen,* Michael Centola,* Akio Morinobu,* Roberta Visconti,* Daniel L. Kastner,* Josef S. Smolen,† and John J. O’Shea3* Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase essential for signaling via cytokine receptors that comprise the common ␥-chain (␥c), i.e., the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Jak3 is preferentially expressed in hemopoietic cells and is up-regulated upon cell differentiation and activation. Despite the importance of Jak3 in lymphoid development and immune function, the mechanisms that govern its expression have not been defined. To gain insight into this issue, we set out to characterize the Jak3 promoter. The 5؅-untranslated region of the Jak3 gene is interrupted by a 3515-bp intron. Upstream of this intron and the transcription initiation site, we identified an ϳ1-kb segment that exhibited lymphoid-specific promoter activity and was responsive to TCR signals. Truncation of this fragment revealed that core promoter activity resided in a 267-bp fragment that contains putative Sp-1, AP-1, Ets, Stat, and other binding sites. Mutation of the AP-1 sites significantly diminished, whereas mutation of the Ets sites abolished, the inducibility of the promoter construct. Chromatin immunoprecipitation assays showed that histone acetylation correlates with mRNA expression and that Ets-1/2 binds this region. Thus, transcription factors that bind these sites, especially Ets family members, are likely to be important regulators of Jak3 expression.
    [Show full text]
  • 942.Full.Pdf
    Original Article Opposite Effect of JAK2 on Insulin-Dependent Activation of Mitogen-Activated Protein Kinases and Akt in Muscle Cells Possible Target to Ameliorate Insulin Resistance Ana C.P. Thirone, Lellean JeBailey, Philip J. Bilan, and Amira Klip Many cytokines increase their receptor affinity for Janus kinases (JAKs). Activated JAK binds to signal transducers and activators of transcription, insulin receptor substrates olypeptides such as erythropoietin, prolactin, (IRSs), and Shc. Intriguingly, insulin acting through its leptin, angiotensin, growth hormone, most inter- own receptor kinase also activates JAK2. However, the leukins, and interferon-␥ bind to receptors that impact of such activation on insulin action remains un- Plack intrinsic kinase activity, recruiting and acti- known. To determine the contribution of JAK2 to insulin vating cytoplasmic tyrosine kinases of the Janus family signaling, we transfected L6 myotubes with siRNA against (JAK) consisting of JAK1, JAK2, JAK3, and Tyk2 (1–3). JAK2 (siJAK2), reducing JAK2 protein expression by 75%. Activated JAK phosphorylates tyrosine residues within Insulin-dependent phosphorylation of IRS1/2 and Shc was not affected by siJAK2, but insulin-induced phosphoryla- itself and the associated receptor forming high-affinity tion of the mitogen-activated protein kinases (MAPKs) binding sites for a variety of signaling proteins containing Src homology 2 and other phosphotyrosine-binding do- extracellular signal–related kinase, p38, and Jun NH2- terminal kinase and their respective upstream kinases mains, including signal transducers and activators of tran- MKK1/2, MKK3/6, and MKK4/7 was significantly lowered scription, insulin receptor substrates (IRSs), and the when JAK2 was depleted, correlating with a significant adaptor protein Shc (1–4).
    [Show full text]
  • Biomarker Testing in Non- Small Cell Lung Cancer (NSCLC)
    The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada. Biomarker testing in non- small cell lung cancer (NSCLC) Copyright © 2020 EMD Serono, Inc. All rights reserved. US/TEP/1119/0018(1) Lung cancer in the US: Incidence, mortality, and survival Lung cancer is the second most common cancer diagnosed annually and the leading cause of mortality in the US.2 228,820 20.5% 57% Estimated newly 5-year Advanced or 1 survival rate1 metastatic at diagnosed cases in 2020 diagnosis1 5.8% 5-year relative 80-85% 2 135,720 survival with NSCLC distant disease1 Estimated deaths in 20201 2 NSCLC, non-small cell lung cancer; US, United States. 1. National Institutes of Health (NIH), National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer website. www.seer.cancer.gov/statfacts/html/lungb.html. Accessed May 20, 2020. 2. American Cancer Society. What is Lung Cancer? website. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed May 20, 2020. NSCLC is both histologically and genetically diverse 1-3 NSCLC distribution by histology Prevalence of genetic alterations in NSCLC4 PTEN 10% DDR2 3% OTHER 25% PIK3CA 12% LARGE CELL CARCINOMA 10% FGFR1 20% SQUAMOUS CELL CARCINOMA 25% Oncogenic drivers in adenocarcinoma Other or ADENOCARCINOMA HER2 1.9% 40% KRAS 25.5% wild type RET 0.7% 55% NTRK1 1.7% ROS1 1.7% Oncogenic drivers in 0% 20% 40% 60% RIT1 2.2% squamous cell carcinoma Adenocarcinoma DDR2 2.9% Squamous cell carcinoma NRG1 3.2% Large cell carcinoma
    [Show full text]
  • Kinase Inhibitors: an Introduction
    David Peters Baran Group Meeting Kinase Inhibitors: An Introduction 2/2/19 INTRODUCTION SIGNAL TRANSDUCTION KINASES ARE IMPORTANT IN HUMAN BIOLOGY/DISEASE: The process describing how a signal (chemical/physical) is transmitted through a - Kinases are a superfamily of proteins (5th largest in humans) cell ultimately resulting in a cellular response - 518 genes and 106 pseudogenes - Diverse in size, subunit structure, and cellular location RECEPTOR TRANSDUCERS EFFECTORS - ~260 residues make up their conserved catalytic core - dysregulation of kinases occurs in many diseases (cancer, inflamatory, degenerative, and autoimmune diseases) - signals can originate inside or outside the cell - 244 of the 518 map to disease loci - signals generally passed through a series of steps (signal transduction pathway) often consisting of multiple enzymes and messengers protein O - pathways open possibility for signal aplification (>1x106) kinase ATP + PROTEIN OH ADP + PROTEIN O P O - Extracellular signals transduced by RTKs, GPCR’s, guanlyl cyclases, or ligand-gated Ion channels O - Phosphorylation is the most prominent covalent modification/signal in KINASES INHIBITORS ARE IMPORTANT IN DISEASE THERAPY/RESEARCH: cellular regulation - currently 51 FDA approved small molecule kinase inhibitors - “converter enzymes” (protein kinases and phosphoprotein phosphorlyases) - 4 FDA approved antibody kinase inhibitors are regulated; conserve ATP/maintain desired target protein state - thousands of known inhibitors spanning the kinome - pathway ends by affecting biomolecule
    [Show full text]
  • Anti-Inflammatory Cytokines Hepatocyte Growth Factor and Interleukin-11 Are Over-Expressed in Polycythemia Vera and Contribute T
    Oncogene (2011) 30, 990–1001 & 2011 Macmillan Publishers Limited All rights reserved 0950-9232/11 www.nature.com/onc ORIGINAL ARTICLE Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F M Boissinot1,3,4, C Cleyrat1,3, M Vilaine1, Y Jacques1, I Corre1 and S Hermouet1,2 1INSERM UMR 892, Institut de Biologie, Centre Hospitalier Universitaire, Nantes, France and 2Laboratoire d’He´matologie, Institut de Biologie, Centre Hospitalier Universitaire, Nantes, France The V617F activating mutation of janus kinase 2 (JAK2), Keywords: Polycythemia vera; JAK2V617F; hepatocyte a kinase essential for cytokine signalling, characterizes growth factor (HGF); interleukin 11 (IL-11); interleukin Polycythemia vera (PV), one of the myeloproliferative 6 (IL-6); inflammation neoplasms (MPN). However, not all MPNs carry mutations of JAK2, and in JAK2-mutated patients, expression of JAK2V617F does not always result in clone expansion. In the present study, we provide evidence that Introduction inflammation-linked cytokines are required for the growth of JAK2V617F-mutated erythroid progenitors. In a first Myeloproliferative neoplasms (MPNs) constitute a series of experiments, we searched for cytokines over- group of three clonal diseases: Polycythemia vera expressed in PV using cytokine antibody (Ab) arrays, and (PV), essential thrombocythemia (ET) and primary enzyme-linked immunosorbent assays for analyses of myelofibrosis. About half of MPN patients present with serum and bone marrow (BM) plasma, and quantitative activating mutations in the janus kinase 2 (JAK2) gene, reverse transcription–PCRs for analyses of cells purified which encodes for a tyrosine kinase essential for the from PV patients and controls.
    [Show full text]
  • The Role of Signaling Pathways in the Development and Treatment of Hepatocellular Carcinoma
    Oncogene (2010) 29, 4989–5005 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The role of signaling pathways in the development and treatment of hepatocellular carcinoma S Whittaker1,2, R Marais3 and AX Zhu4 1Dana-Farber Cancer Institute, Boston, MA, USA; 2The Broad Institute, Cambridge, MA, USA; 3Institute of Cancer Research, London, UK and 4Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA Hepatocellular carcinoma (HCC) is a highly prevalent, malignancy in adults (Pons-Renedo and Llovet, 2003). treatment-resistant malignancy with a multifaceted mole- For the vast majority of patients, HCC is a late cular pathogenesis. Current evidence indicates that during complication of chronic liver disease, and as such, is hepatocarcinogenesis, two main pathogenic mechanisms often associated with cirrhosis. The main risk factors for prevail: (1) cirrhosis associated with hepatic regeneration the development of HCC include infection with hepatitis after tissue damage caused by hepatitis infection, toxins B virus (HBV) or hepatitis C virus (HCV). Hepatitis (for example, alcohol or aflatoxin) or metabolic influ- infection is believed to be the main etiologic factor in ences, and (2) mutations occurring in single or multiple 480% of cases (Anzola, 2004). Other risk factors oncogenes or tumor suppressor genes. Both mechanisms include excessive alcohol consumption, nonalcoholic have been linked with alterations in several important steatohepatitis, autoimmune hepatitis, primary biliary cellular signaling pathways. These pathways are of cirrhosis, exposure to environmental carcinogens (parti- interest from a therapeutic perspective, because targeting cularly aflatoxin B) and the presence of various genetic them may help to reverse, delay or prevent tumorigenesis.
    [Show full text]
  • Epigenetic Gene Regulation by Janus Kinase 1 in Diffuse Large B-Cell Lymphoma
    Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma Lixin Ruia,b,c,1,2, Amanda C. Drennanb,c,1, Michele Ceribellia,1, Fen Zhub,c, George W. Wrightd, Da Wei Huanga, Wenming Xiaoe, Yangguang Lib,c, Kreg M. Grindleb,c,LiLub,c, Daniel J. Hodsona, Arthur L. Shaffera, Hong Zhaoa, Weihong Xua, Yandan Yanga, and Louis M. Staudta,2 aLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892; bDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705; cCarbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705; dBiometric Research Branch, DCTD, National Cancer Institute, NIH, Bethesda, MD 20892; and eDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research/Food and Drug Administration, Jefferson, AR 72079 Contributed by Louis M. Staudt, September 29, 2016 (sent for review July 22, 2016; reviewed by Anthony R. Green and Ross L. Levine) Janus kinases (JAKs) classically signal by activating STAT transcription promote STAT dimerization, nuclear translocation, and binding factors but can also regulate gene expression by epigenetically to cis-regulatory elements to regulate transcription (15, 17). This phosphorylating histone H3 on tyrosine 41 (H3Y41-P). In diffuse large canonical JAK/STAT pathway is deregulated in several hemato- B-cell lymphomas (DLBCLs), JAK signaling is a feature of the activated logic malignancies (16). In DLBCL, STAT3 is activated in the B-cell (ABC) subtype and is triggered by autocrine production of IL-6 ABC subtype and regulates gene expression to promote the sur- and IL-10.
    [Show full text]
  • JAK3 Deficiency, (SCID T-B+)
    JAK3 deficiency, (SCID T-B+) Author: Professor Luigi D. Notarangelo1,2 Creation Date: November 2001 Update: January 2005 1member of the European editorial committee of Orphanet encyclopedia 2Department of Pediatrics, University of Brescia, Spedali Civil, 25123 Brescia, Italy. [email protected] Abstract Keywords Diagnosis criteria/definition Differential diagnosis Prevalence Clinical description Treatment Etiology Diagnostic methods Genetic counseling Antenatal diagnosis Unresolved questions References Abstract JAK3 (Janus Kinase 3) deficiency is an autosomal recessive form of severe combined immune deficiency (SCID). It is characterized by lack of circulating T and NK (Natural Killer) cells and normal number of B lymphocytes. The disease is due to mutations in the JAK3 gene encoding an intracellular tyrosine kinase that is physically and functionally coupled with several cytokine receptors. Identification of gene anomalies has allowed physicians to make the diagnosis (even prenatal), and may prompt novel forms of treatment based on gene therapy. Although a relatively low number of JAK3-deficient subjects have been diagnosed, JAK3 deficiency represents an important cause of autosomal recessive SCID in the United States and its prevalence in Europe appears to be even higher. However it is considered as a rare disease (incidence is between 1/100,000 and 1/1,000,000 live births). JAK3-deficient patients present with the classical clinical features of SCID in the first few months of life, i.e. chronic diarrhea, failure to thrive, recurrent respiratory infection and/or generalized infections from opportunistic pathogens, or signs of graft-versus-host reaction (skin rash, abnormalities of liver function, pancytopenia) from transplacental acquired maternal T cells.
    [Show full text]
  • Kinase-Targeted Cancer Therapies: Progress, Challenges and Future Directions Khushwant S
    Bhullar et al. Molecular Cancer (2018) 17:48 https://doi.org/10.1186/s12943-018-0804-2 REVIEW Open Access Kinase-targeted cancer therapies: progress, challenges and future directions Khushwant S. Bhullar1, Naiara Orrego Lagarón2, Eileen M. McGowan3, Indu Parmar4, Amitabh Jha5, Basil P. Hubbard1 and H. P. Vasantha Rupasinghe6,7* Abstract The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein- coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150 kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug development. Nevertheless, many factors confound the clinical efficacy of these molecules. Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics determine how useful a compound will be in the treatment of a given cancer. This review provides an overview of kinase-targeted drug discovery and development in relation to oncology and highlights the challenges and future potential for kinase-targeted cancer therapies. Keywords: Kinases, Kinase inhibition, Small-molecule drugs, Cancer, Oncology Background Recent advances in our understanding of the fundamen- Kinases are enzymes that transfer a phosphate group to a tal molecular mechanisms underlying cancer cell signaling protein while phosphatases remove a phosphate group have elucidated a crucial role for kinases in the carcino- from protein.
    [Show full text]
  • Advances in Systemic Therapy for HER2-Positive Metastatic Breast Cancer Phuong Khanh H Morrow1, Francisco Zambrana1,2 and Francisco J Esteva1
    Available online http://breast-cancer-research.com/content/11/4/207 Review Advances in systemic therapy for HER2-positive metastatic breast cancer Phuong Khanh H Morrow1, Francisco Zambrana1,2 and Francisco J Esteva1 1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030, USA 2Current address: Department of Medical Oncology, Hospital Infanta Sofia, Paseo de Europa, 34, Madrid 28702, Spain Corresponding author: Phuong Khanh H Morrow, [email protected] Published: 15 July 2009 Breast Cancer Research 2009, 11:207 (doi:10.1186/bcr2324) This article is online at http://breast-cancer-research.com/content/11/4/207 © 2009 BioMed Central Ltd Abstract differentiation, survival, and migration that are associated with Human epidermal growth factor receptor (HER)2 over-expression HER2-positive breast cancers (Figure 1). Thus, women with is associated with a shortened disease-free interval and poor HER2-positive breast cancers exhibit significantly decreased survival. Although the addition of trastuzumab to chemotherapy in disease-free survival and overall survival (OS) [2-5]. the first-line setting has improved response rates, progression-free survival, and overall survival, response rates declined when trastu- This review discusses progress in the treatment of HER2- zumab was used beyond the first-line setting because of multiple positive metastatic breast cancer since the discovery of the mechanisms of resistance. Studies have demonstrated the clinical utility of continuing
    [Show full text]
  • Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia
    cancers Review Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia Kalpana K. Bhanumathy 1,*, Amrutha Balagopal 1, Frederick S. Vizeacoumar 2 , Franco J. Vizeacoumar 1,3, Andrew Freywald 2 and Vincenzo Giambra 4,* 1 Division of Oncology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (A.B.); [email protected] (F.J.V.) 2 Department of Pathology and Laboratory Medicine, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada; [email protected] (F.S.V.); [email protected] (A.F.) 3 Cancer Research Department, Saskatchewan Cancer Agency, 107 Wiggins Road, Saskatoon, SK S7N 5E5, Canada 4 Institute for Stem Cell Biology, Regenerative Medicine and Innovative Therapies (ISBReMIT), Fondazione IRCCS Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, FG, Italy * Correspondence: [email protected] (K.K.B.); [email protected] (V.G.); Tel.: +1-(306)-716-7456 (K.K.B.); +39-0882-416574 (V.G.) Simple Summary: Protein phosphorylation is a key regulatory mechanism that controls a wide variety of cellular responses. This process is catalysed by the members of the protein kinase su- perfamily that are classified into two main families based on their ability to phosphorylate either tyrosine or serine and threonine residues in their substrates. Massive research efforts have been invested in dissecting the functions of tyrosine kinases, revealing their importance in the initiation and progression of human malignancies. Based on these investigations, numerous tyrosine kinase inhibitors have been included in clinical protocols and proved to be effective in targeted therapies for various haematological malignancies.
    [Show full text]